Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 2, 1999, Pages 212-222

  Verduyn, S C ^a   Vos, M A ^a   Leunissen, H D M ^a   Van Opstal, J M ^a   Wellens, H J J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Almokalant; Amiodarone; Dog; Dronedarone; Early afterdepolarizations; Electrophysiology; Monophasic action potentials; Repolarization arrhythmias; Triggered activity; Ventricle

Indexed keywords

ALMOKALANT; AMIODARONE; ANTIARRHYTHMIC AGENT; DRONEDARONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; ELECTROCARDIOGRAPHY; EXTRASYSTOLE; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

ACTION POTENTIALS; ADMINISTRATION, ORAL; AMIODARONE; ANESTHESIA; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOGS; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; INJECTIONS, INTRAVENOUS; MALE; PROPANOLAMINES; TIME FACTORS; TORSADES DE POINTES;

EID: 0032899803     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199902000-00006     Document Type: Article

References (47)

1. Nattel S, Singh BN. Comparative mechanisms of action of anti-arrhythmic drugs. In: Singh BN, Wellens HJJ, Hiraoka M, eds. Electropharmacological control of cardiac arrhythmias. Mount Kisco, New York: Futura Publishing, 1994:207-24.
2. Connolly SJ. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials: amiodarone trials meta-analysis investigators. Lancet 1997;350: 1417-24.
3. CAST investigators. Mortality and morbidity in patients receiving encainide, flecainide and placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
4. ESVEM investigators. The ESVEM trial: electrophysiological study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. Circulation 1989;79:1354-60.
5. Waldo AL, Camm AJ, de Ruyter de H, et al. The SWORD investigators: effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
6. Julian DG, Camm AJ, Janse MJ, Schwartz PJ, Simon P. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
7. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82.
8. Greene HL. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study): CASCADE investigators. Am J Cardiol 1993;72:280-7.
9. Doval HC, Nul DR, Grancielli HO, Perone SV, Bortman GR, Curiel R. Randomised trial of low dose amiodarone in severe congestive heart failure (GESICA). Lancet 1994;344:493-8.
10. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure: CHF STAT investigators. Circulation 1996;93:2128-34.
11. Kowey PR, Levine JH, Herre JM, et al. Randomized double blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent hemodynamically destabilizing ventricular tachycardia or ventricular fibrillation. Circulation 1995;92:3255-63.
12. Scheinman MM, Levine JH, Canmon DS, et al. Dose ranging study of intravenous amiodarone with life threatening ventricular tachyarrhythmias. Circulation 1995;92:3264-72.
13. Wellens HJJ, Brugada P, Abdollah H, Dassen WR. A comparison of the electrophysiological effects of intravenous and oral amiodarone in the same patient. Circulation 1984;69:120-4.
14. Kowey PR, Marinchak RA, Rials SJ, Filart PA. Intravenous amiodarone. J Am Coll Cardiol 1997;29:1190-8.
15. Mitchell LB, Wyse G, Gillis AM, Duff HJ. Electropharmacology of amiodarone therapy initiation: time courses of onset of electrophysiologic and antiarrhythmic effects. Circulation 1989;80: 34-42.
16. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-36.
17. Hii JTY, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT time interval dispersion as a marker of torsade de pointes: disparate effects of class 1A antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-82.
18. Nguyen TP, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy and QT interval. Circulation 1986;74:340-9.
19. Mattioni TA, Zhettin TA, Sermiento JJ, Parker M, Lesch M, Kehou RF. Amiodarone in patients with previous drug mediated torsade de pointes: long term efficacy. Ann Intern Med 1989;111:574-80.
20. Rankin AC, Pringle SD, Cobbe SM. Acute treatment of torsades de pointes with amiodarone: proarrhythmic and antiarrhythmic association of QT prolongation. Am Heart J 1990;119:185-6.
21. Singh BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 1996;78(suppl 4A):41-53.
22. Harris L, Roncucci R, eds. Amiodarone: pharmacology, pharmacokinetics, toxicology, clinical effects. Paris: Medsci Paris, 1986.
23. Manning A, Thisse V, Hodeige D, Richard J, Heyndrickx JP, Chatelain P. SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol 1995;25:252-61.
24. Finance O, Manning A, Chatelain P. Effects of a new amiodarone like agent, SR 33589, in comparison to amiodarone, d,l-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 1995;26:570-6.
25. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589: a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol 1995;279:25-32.
26. Vos MA, Verduyn SC, Gorgels APM, Lipscei GC, Wellens HJJ. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in the dog with chronic atrioventricular block. Circulation 1995;91:864-72.
27. Verduyn SC, Vos MA, Zande van der J, van der Hulst FF, Wellens HJJ. Role of interventricular dispersion of repolarization in acquired torsade de pointes arrhythmias: reversal by magnesium. Cardiovasc Res 1997;34:353-63.
28. Vos MA, Gorgels APM, Lipscei GC, de Groot SHM, Leunissen HDM, Wellens HJJ. Mechanism specific anti-arrhythmic effects of the potassium channel activator levcromakalim against repolarization dependent tachycardias. J Cardiovasc Electrophysiol 1994;5:731-42.
29. Verduyn SC, Vos MA, Zande van der J, Kulcsar A, Wellens HJJ. Further observations to confirm the importance of dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: comparison between almokalant and d-sotalol using the dog as its own control. J Am Coll Cardiol 1997;30:1575-84.
30. Leerssen HM, Vos MA, Dulk den K, Zande van der J, Wellens HJ. Is the ventricular effective refractory period different when determined by incremental versus decremental scanning?: the effect of pacing cycle length, d-sotalol, and levcromakalim. Pacing Clin Electrophysiol 1994;17:2084-9.
31. Viskin S, Heller K, Barron HV, et al. Post extrasystolic U wave augmentation: a new marker of increased arrhythmic risk in patients without the long QT syndrome. J Am Coll Cardiol 1996; 28:1746-52.
32. Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill, 1972.
33. Vos MA, Groot de SHMA, Verduyn SC, et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic complete atrioventricular block is related to cardiac hypertrophy and electrical remodeling. Circulation 1998;98:1125-35.
34. Svernhage E. Torsades de pointes (TdP) during treatment with almokalant [Abstract]. Eur J Cardiac Pacing Electrophysiol 1994; 4(suppl 4):216.
35. Franz MR, Costard A. Frequency dependent effects of quinidine on the relationship between action potential duration and refractoriness in situ. Circulation 1988;77:1174-84.
36. Sassine A, Fajuri A, Hirsch JL, de CM, Masse C, Puech P. Electrophysiological properties of butoprozine studied by multiple intracardiac recordings on the anaesthetized dog. Arch Int Pharmacodyn Ther 1983;261:249-59.
37. Jaillon P, Heckle J, Jais JM, Poveda SJ, Cheymol G. Acute effects of intravenous prifuroline and amiodarone on canine cardiac automaticity, conduction, and refractoriness: J Cardiovasc Pharmacol 1982;4:486-92.
38. Hodeige D, Chatelain, Manning M. SR 33589 - effect on atrial fibrillation in dogs comparison with amiodarone. In: Haunso S, Kjeldsen K, eds. International society for heart research European section meeting. Copenhagen: Bologna Monduzzi Editore, 1994: 681-4.
39. Sanofi Recherche. Clinical investigator's brochure SR33589B. June 1997.
40. Opstal van JM, Verduyn SC, Vos MA, van der Zande J, Wellens HJJ. Homogenization of ventricular repolarization is responsible for suppression of torsade de pointes arrhythmias in dogs [Abstract]. Eur Heart J 1996;17(suppl):417.
41. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29.
42. Gautier P, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiological characterization of dronedarone (SR 33589): a new amiodarone like agent, in cardiac ventricular myocytes [Abstract]. Eur Heart J 1997;18:269.
43. Sosunov EA, Anyukhovsky EP, Rosen MR. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: I. in vitro study. Circulation 1997;96:4011-8.
44. Chezalviel GF, Davy JM, Poirier JM, Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol 1995;26:787-92.
45. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-85.
46. Chezalviel GF, Davy JM, Poirier JM, Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol 1995;26:787-92.
47. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-85.